BPC-157 (Capsules) Body Protection Compound CAS: 137525-51-0 Formula: C 62 H 98 N 16 O 22 M.W.: 1419.5347 g/mol Purity: 99%+ HPLC Verified Ref No.:BPC-0250TA Ref No.:BPCC-0500TA For Research Use Only (RUO) Not for human or veterinary use
this is termed idiopathic pancreatitis
FDA-Approved vs Research Compounds Understanding the distinction between FDA-approved peptides and research-only compounds is essential for evaluating safety: Category Examples Evidence Base Regulation FDA-Approved Semaglutide (Ozempic), Teriparatide (Forteo), Tesamorelin (Egrifta) Phase I-III clinical trials, post-market surveillance Prescription required, manufactured under cGMP Previously Approved Sermorelin (Geref withdrawn 2008) Clinical trial data exists, but product no longer marketed Research use only (currently) Research Only BPC-157, TB-500, Ipamorelin, KPV Preclinical data (varying depth), no completed human trials Sold for laboratory research, not human consumption For the complete list of FDA-approved peptides and their indications, see our FDA Approved Peptides List 2026 guide
S.ChababiW.MayhueM.et al (2015)
The best non-diabetic body-composition anchor favors tirzepatide, about 75:25 fat-to-lean loss in its DXA data versus about 62:38 in semaglutides. This is cross-trial evidence, not a head-to-head maintenance-dose DXA result
Schneider-Helmert D
